{"id":"sodium-divalproate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Somnolence"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Hair loss"},{"rate":"1-5%","effect":"Liver function abnormalities"},{"rate":"1-5%","effect":"Thrombocytopenia"},{"rate":"1-5%","effect":"Allergic reactions"},{"rate":"1-5%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by inhibiting the reuptake of gamma-aminobutyric acid (GABA), a neurotransmitter that helps to calm down brain activity, and by blocking the release of excitatory neurotransmitters such as glutamate and aspartate.","oneSentence":"Sodium valproate is a mood stabilizer that works by reducing the activity of certain brain chemicals that cause mania and seizures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:13.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy"},{"name":"Manic episodes associated with bipolar disorder"}]},"trialDetails":[{"nctId":"NCT03914534","phase":"PHASE4","title":"Bioequivalence Study of Sodium Divalproate Tablets 500 mg","status":"COMPLETED","sponsor":"Tecnoquimicas","startDate":"2017-04-17","conditions":"Healthy","enrollment":30},{"nctId":"NCT02116400","phase":"","title":"Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-01","conditions":"Bipolar Disorder","enrollment":""},{"nctId":"NCT02556320","phase":"NA","title":"Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2013-05","conditions":"Epilepsy, Drug Hypersensitivity Syndrome","enrollment":30},{"nctId":"NCT00271258","phase":"PHASE3","title":"Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-01","conditions":"Bipolar Disorder","enrollment":200}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"BLOOD CREATINE PHOSPHOKINASE INCREASED"},{"count":3,"reaction":"BLOOD PRESSURE SYSTOLIC DECREASED"},{"count":3,"reaction":"COMA"},{"count":3,"reaction":"HEART RATE DECREASED"},{"count":3,"reaction":"INTENTIONAL OVERDOSE"},{"count":3,"reaction":"LUNG DISORDER"},{"count":3,"reaction":"SINUS RHYTHM"},{"count":3,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":2,"reaction":"COAGULOPATHY"},{"count":2,"reaction":"DRUG-INDUCED LIVER INJURY"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SODIUM DIVALPROATE","genericName":"SODIUM DIVALPROATE","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sodium valproate is a small molecule anti-epileptic drug used to treat conditions such as epilepsy. It has also been studied in relation to other conditions including bipolar disorder and drug hypersensitivity syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}